Unknown

Dataset Information

0

Direct and allosteric inhibition of the FGF2/HSPGs/FGFR1 ternary complex formation by an antiangiogenic, thrombospondin-1-mimic small molecule.


ABSTRACT: Fibroblast growth factors (FGFs) are recognized targets for the development of therapies against angiogenesis-driven diseases, including cancer. The formation of a ternary complex with the transmembrane tyrosine kinase receptors (FGFRs), and heparan sulphate proteoglycans (HSPGs) is required for FGF2 pro-angiogenic activity. Here by using a combination of techniques including Nuclear Magnetic Resonance, Molecular Dynamics, Surface Plasmon Resonance and cell-based binding assays we clarify the molecular mechanism of inhibition of an angiostatic small molecule, sm27, mimicking the endogenous inhibitor of angiogenesis, thrombospondin-1. NMR and MD data demonstrate that sm27 engages the heparin-binding site of FGF2 and induces long-range dynamics perturbations along FGF2/FGFR1 interface regions. The functional consequence of the inhibitor binding is an impaired FGF2 interaction with both its receptors, as demonstrated by SPR and cell-based binding assays. We propose that sm27 antiangiogenic activity is based on a twofold-direct and allosteric-mechanism, inhibiting FGF2 binding to both its receptors.

SUBMITTER: Pagano K 

PROVIDER: S-EPMC3351436 | biostudies-literature | 2012

REPOSITORIES: biostudies-literature

altmetric image

Publications

Direct and allosteric inhibition of the FGF2/HSPGs/FGFR1 ternary complex formation by an antiangiogenic, thrombospondin-1-mimic small molecule.

Pagano Katiuscia K   Torella Rubben R   Foglieni Chiara C   Bugatti Antonella A   Tomaselli Simona S   Zetta Lucia L   Presta Marco M   Rusnati Marco M   Taraboletti Giulia G   Colombo Giorgio G   Ragona Laura L  

PloS one 20120514 5


Fibroblast growth factors (FGFs) are recognized targets for the development of therapies against angiogenesis-driven diseases, including cancer. The formation of a ternary complex with the transmembrane tyrosine kinase receptors (FGFRs), and heparan sulphate proteoglycans (HSPGs) is required for FGF2 pro-angiogenic activity. Here by using a combination of techniques including Nuclear Magnetic Resonance, Molecular Dynamics, Surface Plasmon Resonance and cell-based binding assays we clarify the mo  ...[more]

Similar Datasets

| S-EPMC5450166 | biostudies-literature
| S-EPMC10435562 | biostudies-literature
| S-EPMC4802308 | biostudies-literature
| S-EPMC7508794 | biostudies-literature
| S-EPMC198540 | biostudies-literature
| S-EPMC8534529 | biostudies-literature
| S-EPMC6363389 | biostudies-literature
| S-EPMC6308115 | biostudies-literature
| S-EPMC3737738 | biostudies-literature
| S-EPMC3992074 | biostudies-literature